Frontline evaluation: Atezolizumab–bevacizumab versus lenvatinib for <scp>BCLC</scp> stage B hepatocellular carcinoma exceeding the up‐to‐seven criteria

Atez/Bev and LEN demonstrated comparable efficacy and safety as first-line systemic treatments for patients with BCLC stage B HCC exceeding the up-to-seven criteria. Both therapeutic options are viable for this population, though further large-scale prospective studies are required to confirm these findings.